Clinical Trial Detail

NCT ID NCT01868022
Title Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

malignant pleural mesothelioma

lung non-small cell carcinoma

Therapies

Docetaxel

Cisplatin + Pemetrexed Disodium

GSK3052230

Carboplatin + Paclitaxel

Age Groups: adult

Additional content available in CKB BOOST